

Curriculum Vitae
Jason G. Shultz, MD

Practice Address:
Oncologist
July, 2014
Oncology Specialists of Charlotte
2711 Randolph Road, Suite 100
Charlotte, NC 28207
jshultz@oncologycharlotte.com

Site Affiliations:
DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

1992-1996	Bachelor of Science –Biology Davidson College
1998-1999	Graduate Certificate in Anatomy Virginia Commonwealth University/ Medical College of Virginia
2005-2009	Doctor of Medicine Medical University of the Americas
2009-2012	Internal Medicine Internship/Residency University of Oklahoma
2012-2014	Oncology Fellowship East Tennessee State University

Certifications:
American Board of Internal Medicine Certification
Board Certification in Medical Oncology

Professional Experience:

2003-2005	MedCath Diagnostics
2000-2002	Automatic Data Processing, Inc. (ADP)
1996-1998	The Out-of-Door Academy

Presentations:
American College of Physicians (ACP), Oklahoma Chapter. October 2011
Poster Presentation in Clinical Research Category – “Hospital Follow-Up: Getting Discharge Summaries to the Primary Care Physician (PCP).”
Oral Presentation – “Smokers on a Fixed Income: Understanding the Long Term Health and Financial Consequences of Smoking.”

Society of General Internal Medicine (SGIM), Annual Meeting. May 2011
Poster Presentation – “A Brush with Death.”

University of Oklahoma-Tulsa Research Symposium. April 2012
Poster Presentation – “An Unusual Case of Septic Arthritis.”

Curriculum Vitae
Jason G. Shultz, MD

University of Oklahoma-Tulsa Grand Rounds. May 2012
"Smoking Cessation."

Clinical Research:

Sub-Investigator – Novartis Protocol CLEE011A2404: An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor–Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer With No Prior Hormonal Therapy for Advanced Disease (NCT02941926). 2017

Sub-Investigator – Pfizer Madeline Protocol A5481074: Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer. 2017

Sub- Investigator- Merrimack SHERBOC/ MM121-02-02-10 Protocol: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy. 2017

My signature verifies the information in these curriculum vitae is accurate and updated appropriately .


Signature

04 Dec 2017
Date